This program project proposal seeks support for studies on the mechanisms of progression and metastasis of progression and metastasis in carcinoma of the prostate (CaP). CaP is now the nation's #1 cancer and the #2 cancer killer in men. While prostatic specific antigen has revolutionized diagnosis and local therapies, there is no cure for progressive CaP which tends to metastasize almost exclusively to bone and to convert to an androgen independent state following androgen ablation. The proposal is divided into 4 Projects, and 3 Cores. Project I seeks to discover the expression patterns of new and known genes during CaP progress using modern genomic approaches (cDNA libraries, sequencing, microassays) in populations of cells from a variety of CaP tissues and xenograft purified for their basal and luminal cell-like characteristics using high through-put cell sorting techniques and antibodies to a variety of established cell surface markers including CD57 and CD44. Project II seeks to learn about the mechanisms of CaP-bone interactions. The approach will be to examine in vitro and in vitro the influence of several factors in CaP cells that """"""""allow"""""""" CaP-bone implantation, growth and/or the development of the unique osteoblastic response. The factors to be examined include the newly discovered bone regulatory proteins Osteoprotegerin, TRANCE and RANK, the insulin-like growth factor (IGF) and endothelin-1 and the newly discovered prostate specific serine proteases (e.g. Prostase and TMPRSS2) of Project III. Project II seeks to learn more about their two recently discovered prostate specific serine proteases Prostase and TPMRSS2 and to discover and to characterize more of these proteases using modern genomic techniques. The project will also determine whether any of these novel proteases can be used as new serum markers for CaP. Project IV seeks to discovery how known or new growth factors, especially those associated with the IGF system, influence the activation of the androgen receptor or androgen-regulated signaling pathways when CaP progresses to androgen independence. The interactions among the projects are numerous and are facilitated by an extensive Core infrastructure. One Core provides 5 services including specimen acquisition and execution of all xenograft activities. Another Core provides genomic support. The final Core provides comprehensive administrative support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA085859-01A2
Application #
6424562
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mohla, Suresh
Project Start
2002-05-01
Project End
2007-04-30
Budget Start
2002-05-01
Budget End
2003-04-30
Support Year
1
Fiscal Year
2002
Total Cost
$2,008,990
Indirect Cost
Name
University of Washington
Department
Urology
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Montgomery, Bruce; Tretiakova, Maria S; Joshua, Anthony M et al. (2017) Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res 23:2169-2176
Martin, P L; Yin, J-J; Seng, V et al. (2017) Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer. Oncogene 36:525-533
Suominen, Mari I; Fagerlund, Katja M; Rissanen, Jukka P et al. (2017) Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 23:4335-4346
Don-Doncow, Nicholas; Marginean, Felicia; Coleman, Ilsa et al. (2017) Expression of STAT3 in Prostate Cancer Metastases. Eur Urol 71:313-316
Haider, Maahum; Zhang, Xiaotun; Coleman, Ilsa et al. (2016) Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases. Clin Exp Metastasis 33:239-48
Wu, Yu; Davison, Jerry; Qu, Xiaoyu et al. (2016) Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer. Epigenetics 11:247-58
Van Allen, Eliezer M; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget 7:52888-52899
Brocqueville, Guillaume; Chmelar, Renee S; Bauderlique-Le Roy, Hélène et al. (2016) s-SHIP expression identifies a subset of murine basal prostate cells as neonatal stem cells. Oncotarget 7:29228-44
Qu, Xiaoyu; Jeldres, Claudio; Glaskova, Lena et al. (2016) Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence. J Mol Diagn 18:215-24
Wu, Yu; Schoenborn, Jamie R; Morrissey, Colm et al. (2016) High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. J Mol Diagn 18:131-43

Showing the most recent 10 out of 157 publications